NDAVAGINALCREAM
Approved
Oct 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Terconazole is an azole antifungal cream administered vaginally to treat vulvovaginal fungal infections, primarily candidiasis. It works by disrupting fungal cell membrane synthesis through inhibition of lanosterol 14α-demethylase. The drug has been approved since 2004 and remains a standard OTC and prescription option for vaginal yeast infections.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating shrinking team and shift toward line extension or exit strategies.
Mechanism of Action
Pharmacologic Class:
Azole Antifungal
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis
Started Dec 2007
160 enrolled
VaginitisInfectious Vaginosis
Career Relevance
Terconazole offers limited career growth due to zero linked job openings and LOE-approaching lifecycle stage. Positions available are primarily defensive or support roles focused on managing decline and generic competition.
Brand Manager
Worked on TERCONAZOLE at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.